<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01686126</url>
  </required_header>
  <id_info>
    <org_study_id>feMMe</org_study_id>
    <nct_id>NCT01686126</nct_id>
  </id_info>
  <brief_title>Improving the Treatment for Women With Early Stage Cancer of the Uterus</brief_title>
  <acronym>feMMe</acronym>
  <official_title>A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queensland Centre for Gynaecological Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queensland University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queensland Centre for Gynaecological Cancer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently the standard treatment for early stage endometrial cancer or endometrial&#xD;
      hyperplasia with atypia is a total hysterectomy (an operation to remove the uterus) and&#xD;
      removal of both ovaries. While highly effective, this surgery carries significant side&#xD;
      effects for:&#xD;
&#xD;
        -  young women who still wish to have children and would lose fertility; and&#xD;
&#xD;
        -  women with one or more disorders (or diseases) in addition to the early stage&#xD;
           endometrial cancer or endometrial hyperplasia with atypia and/or morbid obesity who are&#xD;
           at risk for surgical complications making surgery unsafe.&#xD;
&#xD;
      This study will access a new approach to the treatment of endometrial cancer to spare women&#xD;
      of having to undergo major surgery that may be unwanted or unnecessary.&#xD;
&#xD;
      Mirena is approved in Australia for contraception, to treat heavy bleeding, and to prevent&#xD;
      thickening of the lining of the uterus (endometrial hyperplasia) during oestrogen replacement&#xD;
      therapy (HRT). However it is not approved to treat early stage endometrial cancer or&#xD;
      endometrial hyperplasia with atypia. This research project will test to see if Mirena is an&#xD;
      effective treatment for early stage endometrial cancer and endometrial hyperplasia with&#xD;
      atypia.&#xD;
&#xD;
      Metformin is approved in Australia to treat Diabetes. However it is not approved to treat&#xD;
      early stage endometrial cancer or endometrial hyperplasia with atypia. Therefore, it is an&#xD;
      experimental treatment for early stage endometrial cancer and endometrial hyperplasia with&#xD;
      atypia. This means that it must be tested to see if it is an effective treatment for early&#xD;
      stage endometrial cancer and endometrial hyperplasia with atypia.&#xD;
&#xD;
      Weight loss interventions are feasible and safe, and already being implemented by&#xD;
      gynaecologic oncologist to make women eligible for surgery. Weight loss of 7% body weight&#xD;
      induces a large biological effect (for example reduces incidence of diabetes by 58%, and&#xD;
      hypertension by 26%).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predict the response to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>To predict the response to treatment through blood and tissue molecular biomarkers and to increase our molecular understanding of the biological pathogenesis of &quot;early&quot; EAC.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Complex Endometrial Hyperplasia With Atypia</condition>
  <condition>Grade 1 Endometrial Endometrioid Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Mirena + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirena</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirena + Weight Loss Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel</intervention_name>
    <description>Intrauterine device</description>
    <arm_group_label>Mirena</arm_group_label>
    <arm_group_label>Mirena + Metformin</arm_group_label>
    <arm_group_label>Mirena + Weight Loss Intervention</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>oral medication</description>
    <arm_group_label>Mirena + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females with a BMI &gt; 30 kg/m2 wishing to retain fertility or females who are at high&#xD;
             risk of surgical complications due to co-morbidities or obesity&#xD;
&#xD;
          2. Over 18 years of age at time of randomisation&#xD;
&#xD;
          3. Histologically confirmed complex endometrial hyperplasia with atypia or grade 1&#xD;
             endometrioid endometrial adenocarcinoma on a curette or endometrial biopsy&#xD;
&#xD;
          4. CT or MRI scan of pelvis, abdomen and chest (or chest X-Ray) suggesting the absence of&#xD;
             extrauterine disease&#xD;
&#xD;
          5. Myometrial invasion on MRI of not more than 50%, for women with histologically&#xD;
             confirmed Endometrial Cancer only (for women who are unable to fit into an MRI machine&#xD;
             inclusion into trial is at investigators discretion)&#xD;
&#xD;
          6. No lymph vascular invasion on curetting or pipelle, if able to be assessed on sample&#xD;
&#xD;
          7. Serum CA125 ≤ 30 U/mL&#xD;
&#xD;
          8. No hypersensitivity or contraindications for Mirena&#xD;
&#xD;
          9. Ability to comply with endometrial biopsies at specified intervals&#xD;
&#xD;
         10. Negative serum or urine pregnancy test in pre-menopausal women and women &lt; 2 years&#xD;
             after the onset of menopause&#xD;
&#xD;
         11. Creatinine &lt; 150µmol/L (1.7 mg/dL) to be randomised into Mirena + Metformin arm (can&#xD;
             still be eligible to be randomised to Mirena only or Mirena + Weight Loss, see section&#xD;
             5.4 Other Eligibility Criteria Considerations)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ECOG performance status &gt; 3&#xD;
&#xD;
          2. Grade 1 endometrioid adenocarcinoma of the endometrium with myometrial invasion deeper&#xD;
             than 50% on MRI or any patients with grade 2 or grade 3 endometrioid adenocarcinoma&#xD;
&#xD;
          3. Histological (cell) type other than endometrioid adenocarcinoma (sarcomas or high risk&#xD;
             endometrial e.g. papillary serous, clear cell)&#xD;
&#xD;
          4. Pregnant or planning to become pregnant during trial period&#xD;
&#xD;
          5. Has had prior treatment or undergoing current treatment for EAC or EHA&#xD;
&#xD;
          6. Patients with a history of pelvic or abdominal radiotherapy&#xD;
&#xD;
          7. Unwilling to have additional endometrial biopsies or curettes and unable to attend&#xD;
             three monthly clinical assessments&#xD;
&#xD;
          8. Unable to provide informed consent&#xD;
&#xD;
          9. Unable or unwilling to complete questionnaires&#xD;
&#xD;
         10. Evidence of extrauterine spread on medical imaging&#xD;
&#xD;
         11. Congenital or acquired uterine anomaly which distorts the uterine cavity&#xD;
&#xD;
         12. Acute pelvic inflammatory disease&#xD;
&#xD;
         13. Conditions associated with increased susceptibility to infections with microorganisms&#xD;
             (e.g., AIDS, leukaemia, IV drug abuse) according to the patients Medical History&#xD;
&#xD;
         14. Genital actinomycosis&#xD;
&#xD;
         15. Current other cancer, except low grade malignancies that do not require any systemic&#xD;
             treatment or treatment to the pelvis&#xD;
&#xD;
         16. Breastfeeding mothers&#xD;
&#xD;
         17. Mirena inserted greater than 12 weeks before randomisation/enrolment&#xD;
&#xD;
         18. Previous use of Mirena within the last 5 years from randomisation/enrolment&#xD;
&#xD;
         19. Contraindications to both Metformin and weight loss&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Obermair</last_name>
    <role>Study Chair</role>
    <affiliation>Queensland Centre for Gynaecological Cancer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wesley Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Health Services, Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Women's Hospital</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Edward Memorial Hospital for Women</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John of God Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6904</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Women's Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2012</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial hyperplasia</keyword>
  <keyword>endometrial adenocarcinoma</keyword>
  <keyword>Gynecological Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

